HC Wainwright Reiterates Buy Rating for Wave Life Sciences (NASDAQ:WVE)

HC Wainwright restated their buy rating on shares of Wave Life Sciences (NASDAQ:WVE) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price target on the stock.

WVE has been the topic of several other research reports. Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 target price on the stock. Mizuho boosted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, February 27th. Finally, Truist Financial boosted their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Wave Life Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

Wave Life Sciences Stock Down 5.9 %

Shares of WVE opened at $10.57 on Wednesday. Wave Life Sciences has a 52-week low of $4.25 and a 52-week high of $16.74. The firm’s fifty day moving average is $11.58 and its two-hundred day moving average is $11.19. The stock has a market cap of $1.61 billion, a PE ratio of -9.52 and a beta of -1.09.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Wave Life Sciences in the fourth quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after buying an additional 856 shares during the last quarter. Quarry LP acquired a new position in Wave Life Sciences in the fourth quarter valued at about $62,000. KBC Group NV acquired a new position in Wave Life Sciences in the fourth quarter valued at about $67,000. Finally, Summit Investment Advisors Inc. increased its stake in Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares during the period. Institutional investors and hedge funds own 89.73% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.